癌症进展
癌癥進展
암증진전
ONCOLOGY PROGRESS
2014年
5期
483-487
,共5页
蒋劲松%黎皓%耿梅%任若冰%瞿晴%曹卫国%金冶宁
蔣勁鬆%黎皓%耿梅%任若冰%瞿晴%曹衛國%金冶寧
장경송%려호%경매%임약빙%구청%조위국%금야저
食管肿瘤%奈达铂%顺铂%紫杉醇%化疗
食管腫瘤%奈達鉑%順鉑%紫杉醇%化療
식관종류%내체박%순박%자삼순%화료
Esophageal cancer%nedaplatin%cisplatin%paclitaxel%chemotherapy
目的：评价并比较奈达铂/顺铂联合紫杉醇治疗晚期食管癌的疗效和不良反应。方法回顾性分析2006年至2011年收治的80例接受奈达铂联合紫杉醇（41例）或顺铂联合紫杉醇（39例）治疗的晚期食管癌患者，对比两种治疗方法的疗效及不良反应。结果奈达铂联合紫杉醇组（TN组）缓解率为26.8%；顺铂联合紫杉醇组（TP组）缓解率为23.1%，两组间差异无统计学意义（P＝0.603）；TN组和TP组的中位疾病进展时间（time to progress，TTP）和中位总生存时间（overall survival，OS）分别为6个月和5个月、11个月和10个月，差异具有统计学意义（P＝0.003，P＝0.068）。常见的毒副反应主要是消化道毒性，血液学毒性和脱发。奈达铂组消化道毒性发生率及严重程度显著低于顺铂组，差异具有统计学意义（P＝0.0001）。结论奈达铂联合紫杉醇治疗晚期食管癌患者其疗效和总生存与顺铂联合紫杉醇相似，但是在疾病无进展时间和消化道毒性发生率及严重程度上，奈达铂较顺铂有着显著的优势。
目的：評價併比較奈達鉑/順鉑聯閤紫杉醇治療晚期食管癌的療效和不良反應。方法迴顧性分析2006年至2011年收治的80例接受奈達鉑聯閤紫杉醇（41例）或順鉑聯閤紫杉醇（39例）治療的晚期食管癌患者，對比兩種治療方法的療效及不良反應。結果奈達鉑聯閤紫杉醇組（TN組）緩解率為26.8%；順鉑聯閤紫杉醇組（TP組）緩解率為23.1%，兩組間差異無統計學意義（P＝0.603）；TN組和TP組的中位疾病進展時間（time to progress，TTP）和中位總生存時間（overall survival，OS）分彆為6箇月和5箇月、11箇月和10箇月，差異具有統計學意義（P＝0.003，P＝0.068）。常見的毒副反應主要是消化道毒性，血液學毒性和脫髮。奈達鉑組消化道毒性髮生率及嚴重程度顯著低于順鉑組，差異具有統計學意義（P＝0.0001）。結論奈達鉑聯閤紫杉醇治療晚期食管癌患者其療效和總生存與順鉑聯閤紫杉醇相似，但是在疾病無進展時間和消化道毒性髮生率及嚴重程度上，奈達鉑較順鉑有著顯著的優勢。
목적：평개병비교내체박/순박연합자삼순치료만기식관암적료효화불량반응。방법회고성분석2006년지2011년수치적80례접수내체박연합자삼순（41례）혹순박연합자삼순（39례）치료적만기식관암환자，대비량충치료방법적료효급불량반응。결과내체박연합자삼순조（TN조）완해솔위26.8%；순박연합자삼순조（TP조）완해솔위23.1%，량조간차이무통계학의의（P＝0.603）；TN조화TP조적중위질병진전시간（time to progress，TTP）화중위총생존시간（overall survival，OS）분별위6개월화5개월、11개월화10개월，차이구유통계학의의（P＝0.003，P＝0.068）。상견적독부반응주요시소화도독성，혈액학독성화탈발。내체박조소화도독성발생솔급엄중정도현저저우순박조，차이구유통계학의의（P＝0.0001）。결론내체박연합자삼순치료만기식관암환자기료효화총생존여순박연합자삼순상사，단시재질병무진전시간화소화도독성발생솔급엄중정도상，내체박교순박유착현저적우세。
Objective To evaluate the efficacy and toxicity of nedaplatin or cisplatin combined with paclitaxel as first-line chemotherapy for patients with advanced esophageal cancer. Method A total of 80 patients with pathologi-cally confirmed and measurable lesions were enrolled and separated into either TN group (nedaplatin + paclitaxel) or TP group (cisplatin + paclitaxel) according to the respective chemotherapy regimen, and then all patients were fol-lowed up and the time to progress (TTP) and overall survival (OS) were analyzed. Result In terms of TN group (41 cases) vs TP group (39 cases), the response rate was 26.8% (11/41) vs 23.1% (10/39), with no statistical signifi-cance (P=0.603), the median TTP was significantly more in TN group as 6 months vs 5 months (P=0.003), and the median overall survival rate was also higher as 11 months vs 10 months (P=0.068); As to the most common adverse reactions, hematologic and gastrointestinal toxicities were included, however, the incidence of gastrointestinal toxicity in TP group was significantly lower than that in TN group (P=0.0001). Conclusion The combined chemo-therapy of nedaplatin + paclitaxel is as effective as the regimen of cisplatin + paclitaxel, while the TN regimen is su-perior with longer TTP and less gastrointestinal toxicity.
